ADVENT ADVANCES IN TYPE 2 IMMUNE DISEASES Trademark

Trademark Overview

On Thursday, October 12, 2017, a trademark application was filed for ADVENT ADVANCES IN TYPE 2 IMMUNE DISEASES with the United States Patent and Trademark Office. The USPTO has given the ADVENT ADVANCES IN TYPE 2 IMMUNE DISEASES trademark a serial number of 87643233. The federal status of this trademark filing is REGISTERED as of Tuesday, February 12, 2019. This trademark is owned by Sanofi Biotechnology. The ADVENT ADVANCES IN TYPE 2 IMMUNE DISEASES trademark is filed in the Education & Entertainment Services category with the following description:

Educational services, namely, arranging and conducting classes, seminars, conferences, and workshops for patients with immune system related diseases and disorders, namely, asthma, atopic dermatitis, and nasal polyposis, in the fields of immunology and inflammatory diseases
advent advances in type 2 immune diseases

General Information

Serial Number87643233
Word MarkADVENT ADVANCES IN TYPE 2 IMMUNE DISEASES
Filing DateThursday, October 12, 2017
Status700 - REGISTERED
Status DateTuesday, February 12, 2019
Registration Number5672358
Registration DateTuesday, February 12, 2019
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, August 7, 2018

Trademark Statements

Goods and ServicesEducational services, namely, arranging and conducting classes, seminars, conferences, and workshops for patients with immune system related diseases and disorders, namely, asthma, atopic dermatitis, and nasal polyposis, in the fields of immunology and inflammatory diseases
Description of MarkThe mark consists of the stylized wording "ADVENT" below two slightly offset chevrons facing the opposite direction. The letters "AD" appear in a dark teal, whereas the letters "VENT" appear in a light teal. The left-pointing chevron is shaded light gray to dark gray from left to right, and the right-pointing chevron is shaded dark teal to light teal from left to right. A light gray shadow between the two chevrons gives the illusion of depth. The stylized wording "ADVANCES IN TYPE 2 IMMUNE DISEASES" appears in light gray below the wording "ADVENT", the white background represents a transparent area and is not part of the mark.
Pseudo MarkADVENT ADVANCES IN TYPE TWO IMMUNE DISEASES; ADVENT ADVANCES IN TYPE TO IMMUNE DISEASES
Indication of Colors claimedThe color(s) light teal, dark teal, light gray, and dark gray is/are claimed as a feature of the mark.
Disclaimer with Predetermined Text"ADVANCES IN TYPE 2 IMMUNE DISEASES"

Classification Information

International Class041 - Education; providing of training; entertainment; sporting and cultural activities.
US Class Codes100, 101, 107
Class Status Code6 - Active
Class Status DateFriday, October 20, 2017
Primary Code041
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSanofi Biotechnology
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressParis 75008
FR
Party NameSanofi Biotechnology
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParis 75008
FR
Party NameSanofi Biotechnology
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParis 75008
FR

Trademark Events

Event DateEvent Description
Monday, February 12, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, January 31, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, January 31, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, February 12, 2019REGISTERED-PRINCIPAL REGISTER
Saturday, January 5, 2019TTAB RELEASE CASE TO TRADEMARKS
Saturday, January 5, 2019OPPOSITION TERMINATED NO. 999999
Saturday, January 5, 2019OPPOSITION DISMISSED NO. 999999
Friday, October 19, 2018OPPOSITION INSTITUTED NO. 999999
Wednesday, September 5, 2018EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, August 7, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 7, 2018PUBLISHED FOR OPPOSITION
Wednesday, July 18, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 3, 2018LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, July 2, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 23, 2018NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, May 23, 2018FINAL REFUSAL E-MAILED
Wednesday, May 23, 2018FINAL REFUSAL WRITTEN
Thursday, May 3, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 3, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, April 27, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, March 14, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 14, 2018NON-FINAL ACTION E-MAILED
Wednesday, March 14, 2018NON-FINAL ACTION WRITTEN
Wednesday, February 21, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 21, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, February 14, 2018ASSIGNED TO LIE
Tuesday, February 6, 2018TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Friday, February 2, 2018NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, February 2, 2018LETTER OF SUSPENSION E-MAILED
Friday, February 2, 2018SUSPENSION LETTER WRITTEN
Friday, February 2, 2018PREVIOUS ALLOWANCE COUNT WITHDRAWN
Monday, January 29, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, January 29, 2018EXAMINER'S AMENDMENT ENTERED
Monday, January 29, 2018NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, January 29, 2018EXAMINERS AMENDMENT E-MAILED
Monday, January 29, 2018EXAMINERS AMENDMENT -WRITTEN
Wednesday, January 24, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 23, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, January 23, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, December 9, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, December 9, 2017NON-FINAL ACTION E-MAILED
Saturday, December 9, 2017NON-FINAL ACTION WRITTEN
Thursday, November 30, 2017ASSIGNED TO EXAMINER
Saturday, October 21, 2017NOTICE OF DESIGN SEARCH CODE E-MAILED
Friday, October 20, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, October 16, 2017NEW APPLICATION ENTERED

Related Keywords

diseases immune type advances advent namely atopic asthma disorders dermatitis polyposis inflammatory immunology fields